Cumulus Neuroscience and DiMe Partner on Framework for Digital Endpoints

India Pharma Outlook Team | Friday, 14 June 2024

 digital health, digital endpoints, India Pharma Outlook

Cumulus Neuroscience, a worldwide digital health company dedicated to improving data for neuroscience clinical trials and patient care, has announced a collaboration with the Digital Health Measurement Collaborative Community (DATAcc) of the Digital Medicine Society (DiMe).

Cumulus will take part in the DATAcc by DiMe Building the Business Case for Digital Endpoints project, which will bring together industry leaders to establish common industry benchmarks for assessing the return on investment (ROI) of digital endpoints in the development of drugs, medical devices, and other regulated actions. The project will produce a value framework, industry benchmarking tools, ROI forecasting models, and a modular template to assist innovators in developing the business case for digital endpoints, as well as the development, implementation, and scaling of fit-for-purpose digital measures as endpoints in clinical trials.

"The value of using digital measures in clinical research is significant, but still adopters often struggle to make the case for broader use," said Victoria Bangieva, programme director of DiMe. "At DiMe, we're committed to advancing the use of digital health measures in research to improve lives, and we value the contribution from key partners like Cumulus Neuroscience to develop resources that will help drive the industry towards increased utilization."

Cumulus previously participated in the DATAcc by DiMe Library of Digital Endpoints initiative, which created the sole library dedicated to industry-sponsored research on innovative medical goods or applications. 

© 2024 India Pharma Outlook. All Rights Reserved.